The global radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) market is projected to grow from USD 3.24 billion in 2025 to approximately USD 8.50 billion by 2035, with a compound annual growth rate (CAGR) of 10.12%. Key drivers of this growth include the rising trend of outsourcing in the pharmaceutical industry and advancements in nuclear medicine, particularly in the context of cancer treatment and theranostics. The fluorine-18 segment dominated the market in 2025, largely due to its extensive use in PET imaging for oncology applications, while diagnostic radiopharmaceuticals accounted for the largest market share by application. North America currently leads the market, bolstered by a strong healthcare framework and favorable FDA regulations, whereas the Asia Pacific region is expected to experience the fastest growth due to increasing investments in healthcare infrastructure and rising demand for precision medicine.
Mon, 19 Jan 2026 13:36:10 GMT | Precedence Research